GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK publishes Prospectus and Circular for proposed demerger of its Consumer Healthcare business to form Haleon

For investors and media onlyFurther to the announcement made earlier today regarding the proposed separation of the GSK Consumer Healthcare business from the GSK Group, GSK confirms tha... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

For investors and media onlyIssued: 31 May 2022, London UK - LSE announcement- GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones- Proposed acqui... Read More
GSK
3 years ago ⋅ English ⋅ 22 min read
Newsroom
ViiV Healthcare announces marketing approval by Japan’s Ministry of Health, Labour and Welfare for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine)

For media and investors onlyLong-acting treatment enables people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year after initiationViiV Healthcare,... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces further appointments to Designate Haleon Board

Demerger and listing of Haleon expected in July 2022For media and investors onlyGSK plc (LSE/NYSE: GSK) has today announced the appointments of Asmita Dubey, Marie-Anne Aymerich and Bry... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus

For media and investors only- China’s National Medical Products Administration (NMPA) has approved a two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years for... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
ViiV  Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool

ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent PoolFor media and investors onlyViiV Healthcare and MPP... Read More